Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, open-label, flexible-dose, long-term safety extension study of Lu AF11167 in patients with schizophrenia

Next Previous
Trial Profile

Interventional, open-label, flexible-dose, long-term safety extension study of Lu AF11167 in patients with schizophrenia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lu AF11167 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Lundbeck A/S

Most Recent Events

  • 12 Jun 2022 Results (n=162) of this study and the double-blind study reporting data collected up to study termination, were published in the European Neuropsychopharmacology.
  • 08 Nov 2020 This trial is completed in Germany and Poland (Global End Date: 14 Sep 2020), according to European Clinical Trials Database record.
  • 21 Sep 2020 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top